Docetaxel Injection, Solution, Concentrate
Product Images NDC 67457-781

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Docetaxel (NDC 67457-781). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Mylan Institutional Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Carton Mdv (Image 01)

Box label for Docetaxel Injection, USP 160 mg/8 mL (20 mg/mL) multiple-dose vial by Mylan Institutional LLC. The label states the drug is for intravenous infusion only and is ready to add to infusion solution. It carries a caution for cytotoxic agent and includes storage and usage instructions.*

FDA Label Image

Container Label (Image 02)

Label for Docetaxel Injection, USP 160 mg/8 mL (20 mg/mL) concentrate for intravenous infusion. The one-vial formulation is labeled as sterile and contains a caution for cytotoxic agent use. Manufactured by Mylan Institutional LLC, the label includes storage instructions and a barcode.*

FDA Label Image

Structure (Image 03)

Chemical structure diagram of docetaxel, showing its complex molecular arrangement with multiple rings, hydroxyl groups, methyl groups, and aromatic rings as depicted in the black line drawing.*

FDA Label Image

Graph 1 (Image 04)

A line graph depicting Disease Free Survival (DFS) Probability (%) over time in months, comparing two groups labeled TAC (solid line) and FAC (dotted line). The y-axis shows DFS Probability from 0% to 100%, and the x-axis shows Disease Free Survival Time in months from 0 to 66. The TAC group maintains a higher survival probability than the FAC group throughout the timeline.*

FDA Label Image

Graph 2 (Image 05)

A survival probability chart comparing two treatment groups, TAC and FAC, over a survival period of up to 66 months. The y-axis shows survival probability in percentage, and the x-axis shows survival time in months. TAC is represented by a solid line, and FAC by a dotted line, with both showing a gradual decrease in survival probability over time.*

FDA Label Image

Graph 3 (Image 06)

A Kaplan-Meier survival curve graph comparing overall survival between two groups labeled T75 (solid line) and BSC (dashed line). The x-axis shows survival time in months, ranging from 0 to 21, and the y-axis shows cumulative probability from 0.0 to 1.0. The graph includes a log-rank p-value of 0.010 indicating statistical comparison of survival distributions.*

FDA Label Image

Graph 4 (Image 07)

A Kaplan-Meier survival curve chart depicting overall survival for two groups, T75 (solid line) and V/I (dashed line), showing cumulative probability over survival time in months. The chart includes a log-rank p-value of 0.13 indicating statistical comparison between the groups.*

FDA Label Image

Graph 5 (Image 08)

A survival probability curve graph displaying survival time in months on the x-axis and survival probability on the y-axis. Two lines represent different treatment groups: a solid line labeled T75 q3w and a dashed line labeled M q3w, showing trends in survival probabilities over time up to 30 months.*

FDA Label Image

Graph 6 (Image 09)

A line chart showing survival probability over time in months comparing two treatment groups labeled TCF (solid line) and CF (dotted line). The y-axis represents probability (%) ranging from 0 to 100, and the x-axis represents time in months from 0 to 24. The TCF group maintains higher survival probability over time compared to the CF group, with both declining as time increases.*

FDA Label Image

Graph 7 (Image 10)

A Kaplan-Meier survival curve chart showing survival probability (%) versus survival time (months) for two groups labeled as TCF (solid line) and CF (dashed line). The chart plots survival probability declining over 36 months with TCF group demonstrating higher survival rates compared to the CF group over time.*

FDA Label Image

Graph 8 (Image 11)

A Kaplan-Meier survival curve chart showing progression free survival (PFS) probability over time in months. Two treatment groups are compared: TPF (solid line) and PF (dotted line). The y-axis represents PFS probability in percentage, and the x-axis shows progression free survival time in months, ranging up to 42 months.*

FDA Label Image

Graph 9 (Image 12)

A survival probability curve chart showing survival time in months on the x-axis (0 to 72 months) and survival probability percentage on the y-axis (0% to 100%). Two curves are displayed: a solid line labeled TPF and a dotted line labeled PF, with TPF showing higher survival probabilities over time compared to PF.*

FDA Label Image

Graph 10 (Image 13)

A Kaplan-Meier survival curve comparing survival probability (%) over time in months for two patient groups labeled TPF and PF. The graph shows the number of patients at risk for each group at multiple time points up to 72 months, with TPF group starting at 255 patients and PF group at 2248 patients.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.